Multicenter, prospective interventional study to evaluate therapeutic effect of Afatinib in patients with advanced non-small cell lung cancer, EGFR mutation positive and brain metastasis
Not Applicable
- Conditions
- ung Cancer
- Registration Number
- JPRN-UMIN000031117
- Lead Sponsor
- First Department of Internal Medicine, Shinshu University
- Brief Summary
In one enrolled case, treatment with Afatinib reduced the SUVmax and LNRmax rates of brain metastases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
Not provided
Exclusion Criteria
1)Idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, drug pneumonia, etc. are complicated 2)Active other malignancy 3)Adjuvant chemotherapy 4)Infection to need to treat with antibiotics or antifungal agent via intravenous administration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate amino acid metabolic reactions obtained by followings To evaluate MET-PET/CT at baseline (SUVmax,L/N ratio) To evaluate MET-PET/CT at 4 and 8 weeks after start of therapy (SUVmax,L/N ratio)
- Secondary Outcome Measures
Name Time Method To evaluate relationship between amino acid metabolic reactions and following points PFS OS Response rate TTF Disease control rate